Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1046-1049

  Desire, Salamun ^a   Balasubramanian, Poonkuzhali ^a   Bajel, Ashish ^a   George, Biju ^a   Viswabandya, Auro ^a   Mathews, Vikram ^a   Srivastava, Alok ^a   Chandy, Mammen ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

6 Mercaptopurine; Acute lymphoblastic leukemia; Polymorphism; TPMT

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTOSINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; THIOPURINE METHYLTRANSFERASE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLELE; ARTICLE; CHILD; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INDIA; MALE; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 79951768115     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9331-8     Document Type: Article

References (29)

1. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651-62. (Pubitemid 10061685)
2. Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996;6(4):279-90. (Pubitemid 26288618)
3. McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999;9(6):773-6. (Pubitemid 30011941)
4. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996;58(4):694-702. (Pubitemid 26086658)
5. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126(8):608-14. (Pubitemid 27172187)
6. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest. 1998;101(5):1036-44. (Pubitemid 28125282)
7. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997;62(1):60-73. (Pubitemid 27327100)
8. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14(4):567-72. (Pubitemid 30195445)
9. Corominas H, Baiget M. Clinical utility of thiopurine S-methyltransferase genotyping. Am J Pharmacogenomics. 2004;4(1):1-8. (Pubitemid 38325700)
10. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91(23):2001-8.
11. McLeod HL, Relling MV, Liu Q, et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995;85(7):1897-902.
12. Brenner TL, Pui CH, Evan WE. Pharmacogenomics of childhood acute lymphoblastic leukemia. Curr Opin Mol Ther. 2001;3(6):567-78. (Pubitemid 34041266)
13. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3(1):89-98. (Pubitemid 34285242)
14. Bajel A, George B, Mathews V, et al. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatr Blood Cancer. 2008;51(5):621-5.
15. Bajel A, George B, Mathews V, et al. Adult ALL: treatment outcome and prognostic factors in an Indian population using a modified German ALL (GMALL) protocol. Leukemia. 2007;21(10):2230-3. (Pubitemid 47423828)
16. Stanulla M, Schaeffeler E, Moricke A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols. Blood. 2009;114(7):1314-8.
17. Kham SK, Tan PL, Tay AH, et al. Thiopurine methyltransferase polymorphisms in a multiracial asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2002;24(5):353-9. (Pubitemid 34774004)
18. Ameyaw MM, Collie-Duguid ES, Powrie RH, et al. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8(2):367-70. (Pubitemid 29054280)
19. Kham SK, Soh CK, Liu TC, et al. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol. 2008;64(4):373-9.
20. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9(1):37-42. (Pubitemid 29176722)
21. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14(7):407-17. (Pubitemid 38971231)
22. Ganiere-Monteil C, Medard Y, Lejus C, et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol. 2004;60(2):89-96. (Pubitemid 38626437)
23. Boson WL, Romano-Silva MA, Correa H, et al. Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J. 2003;3(3):178-82. (Pubitemid 36850159)
24. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19(8):2293-301. (Pubitemid 32366982)
25. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol. 1999;105(3):696-700. (Pubitemid 29277028)
26. Spire-Vayron De La Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol. 1998;125(4):879-87. (Pubitemid 28482633)
27. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. Jama. 2005;293(12):1485-9. (Pubitemid 40393293)
28. Ma XL, Zhu P, Wu MY, et al. Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia. Zhonghua Er Ke Za Zhi. 2003;41(12):929-33.
29. Hongeng S, Sasanakul W, Chuansumrit A, et al. Frequency of thiopurine S-methyltransferase genetic variation in Thai children with acute leukemia. Med Pediatr Oncol. 2000;35(4):410-4.